A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19

SARS-CoV-2 Clinical Trial

— TeenCove  

Official title:

A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 Years of Age

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04649151
• Other study ID #: mRNA-1273-P203
• Secondary ID: 2023-000382-14
• Status: Active, not recruiting
• Phase: Phase 2/Phase 3
• Start date: December 9, 2020
• Est. completion date: December 9, 2024

Study information

• Verified date: January 2024
• Source: ModernaTX, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The mRNA-1273 vaccine is being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection. The study is designed to primarily evaluate the safety, reactogenicity, and effectiveness of mRNA-1273 vaccine administered as primary series and a booster dose (BD) to an adolescent population. The study will also evaluate the safety and immunogenicity of an mRNA-1273.222 vaccine against the SARS-CoV- 2 omicron variant as a primary series.

Description:

This is a Phase 2/3 study, with Part 1A (Blinded Phase), Part 1B (Open-label Observational Phase), Part 1C (Booster Dose [BD] Phase), which consists of Part 1C-1 and Part 1C-2, Part 2 (Open-Label), and Part 3 (Open-label). Participants in Part 1A are blinded to their treatment assignment, with participants receiving either 2 active mRNA-1273 vaccine doses or placebo. Part 1B of the study is designed to offer participants whose age group becomes Emergency Use Authorization (EUA) eligible to be unblinded so that participants who received placebo in Part 1A can request 2 doses of open-label mRNA-1273 vaccine. Part 1C-1 of the study will offer participants in Part 1A and Part 1B who are at least 5 months from the last dose, the option to request a homologous BD of mRNA-1273. Part 1C-2 is designed to provide a heterologous BD of mRNA-1273 to eligible participants who completed primary COVID-19 vaccination series with a non-Moderna vaccine under EUA and are at least 3 months from the last dose. Part 2 is an open-label design. Participants will receive 2 doses and may receive a booster dose of mRNA-1273 SARS-CoV-2 vaccine. Part 3 is an open-label design. Participants will receive up to 2 doses of mRNA-1273.222 vaccine.

Please access http://TeenCoveStudy.com for additional information, such as Study Overview, Participation, Site Locations along with contact numbers for each location for the study.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 4331
• Est. completion date: December 9, 2024
• Est. primary completion date: June 9, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 12 Years to 18 Years

Eligibility

Inclusion Criteria:

For Part 1A, Part 2 and Part 3:

• Participants 12 to <18 years of age at the time of consent (Screening Visit, Day 0) who, in the opinion of the Investigator, are in good general health based on review of medical history and screening physical examination.

• Investigator assessment that the participant, in the case of an emancipated minor, or parent(s)/legally acceptable representative(s) (LAR[s]) understand and is willing and physically able to comply with protocol-mandated follow up, including all procedures and provides written informed consent/assent.

• Body mass index (BMI) at or above the third percentile according to World Health Organization (WHO) Child Growth Standards at the Screening Visit (Day 0)

• Female participants of nonchildbearing potential may be enrolled in the study. Nonchildbearing potential is defined as premenarche or surgically sterile (history of bilateral tubal ligation, bilateral oophorectomy, hysterectomy).

• Female participants of childbearing potential may be enrolled in the study if the participant has a negative pregnancy test at Screening (Day 0), on the day of the first injection (Day 1), on the day of the second injection (Day 29 in Parts 1A and Part 2, and Day 181 in Part 3); has practiced adequate contraception or has abstained from all activities that could result in pregnancy for at least 28 days prior to the first injection (Day 1); and has agreed to continue adequate contraception or abstinence through 3 months following the second injection (Day 29 in Part 1A and Part 2, and Day 181 in Part 3).

For Part 1B:

• Participants must have been previously enrolled in mRNA-1273-P203 study.

• Female participants of childbearing potential may be enrolled in the study if the participant has a negative pregnancy test on the day of the first injection (Open-Label-Day 1) and on the day of the second injection (Open-Label-Day 29).

For Part 1C-1 Homologous Booster Dose:

• Participants must have been previously enrolled in the mRNA-1273-P203 study, are actively participating in Part 1A or Part 1B and are least 5 months from the last dose.

• Female participants of childbearing potential may be enrolled in the study if the participant has a negative pregnancy test on the day of the first injection (BD-Day 1).

Part 1C-2 Heterologous Booster Dose:

• Male or female, 12 to < 18 years of age at the time of consent who, in the opinion of the investigator, is in good general health based on review of medical history and screening physical examination AND has completed non-Moderna primary COVID-19 vaccination series under EUA (for example, Pfizer) at least 3 months from consent.

Exclusion Criteria:

For Part 1A, Part 2, and Part 3:

• Has a known history of SARS-CoV-2 infection within 2 weeks prior to administration of investigational product (IP) or known close contact with anyone with laboratory-confirmed SARS-CoV-2 infection of COVID-19 within 2 weeks prior to administration of IP (Part 2 participants only). For Part 3 participants, known history of SARS-CoV-2 infection within 90 days prior to administration of IP or known close contact with anyone with laboratory-confirmed SARS-CoV-2 infection or COVID-19 within 90 days prior to administration of IP.

• Travel outside of the United States or home country (Part 2 and Part 3 only) in the 28 days prior to the Screening Visit (Day 0).

• Pregnant or breastfeeding

• Is acutely ill or febrile 24 hours prior to or at the Screening Visit (Day 0). Fever is defined as a body temperature =38.0°Celsius (C)/=100.4°Farenheit (F). Participants who meet this criterion may have visits rescheduled within the relevant study visit windows. Afebrile participants with minor illnesses can be enrolled at the discretion of the Investigator.

• Prior administration of an investigational coronavirus (for example, SARS-CoV-2, SARS-CoV, Middle East Respiratory Syndrome [MERS-CoV]) vaccine

• Current treatment with investigational agents for prophylaxis against COVID-19

• Has a medical, psychiatric, or occupational condition that may pose additional risk as a result of participation, or that could interfere with safety assessments or interpretation of results according to the Investigator's judgment

• Current use of any inhaled substance (for example, tobacco or cannabis smoke, nicotine vapors)

• History of chronic smoking (=1 cigarette a day) within 1 year of the Screening Visit (Day 0)

• History of illegal substance use or alcohol abuse within the past 2 years. This exclusion does not apply to historical cannabis use that was formerly illegal in the participant's state but is legal at the time of screening.

• History of a diagnosis or condition that, in the judgment of the Investigator, may affect study endpoint assessment or compromise participant safety, specifically:

• Congenital or acquired immunodeficiency, including human immunodeficiency virus (HIV) infection

• Suspected active hepatitis

• Has a bleeding disorder that is considered a contraindication to IM injection or phlebotomy

• Dermatologic conditions that could affect local solicited AR assessments

• History of anaphylaxis, urticaria, or other significant AR requiring medical intervention after receipt of a vaccine

• Diagnosis of malignancy within the previous 10 years (excluding nonmelanoma skin cancer)

• Febrile seizures

• Receipt of:

• Any licensed vaccine within 28 days before the first dose of IP or plans for receipt of any licensed vaccine within 28 days before and/or after each dose of IP.

• Systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to the day of enrollment (for corticosteroids, =20 mg/day prednisone equivalent). Topical tacrolimus is allowed if not used within 14 days prior to the day of enrollment. Participants may have visits rescheduled for enrollment if they no longer meet this criterion within the Screening Visit window. Inhaled, nasal, and topical steroids are allowed.

• Intravenous blood products (red cells, platelets, immunoglobulins) within 3 months prior to enrollment

• Has donated =450 milliliters (mL) of blood products within 28 days prior to the Screening Visit (Day 0) or plans to donate blood products during the study

• Participated in an interventional clinical study within 28 days prior to the Screening Visit (Day 0) or plans to do so while participating in this study

• Is an immediate family member or has a household contact who is an employee of the research center or otherwise involved with the conduct of the study

For Part 1C-1 and Part 1C-2:

• Pregnant or breastfeeding.

• Is acutely ill or febrile 24 hours prior to or at the Screening Visit (Day 0). Fever is defined as a body temperature = 38.0°C/= 100.4°F. Participants who meet this criterion may have visits rescheduled within the relevant study visit windows. Afebrile participants with minor illnesses can be enrolled at the discretion of the investigator.

• Has a medical, psychiatric, or occupational condition that may pose additional risk as a result of participation, or that could interfere with safety assessments or interpretation of results according to the investigator's judgment.

• History of a diagnosis or condition (after enrolment in Part 1A) that, in the judgment of the investigator, may affect study endpoint assessment or compromise participant safety:

• Suspected active hepatitis

• Has a bleeding disorder that is considered a contraindication to IM injection or phlebotomy

• Dermatologic conditions that could affect local solicited AR assessments

• History of anaphylaxis, urticaria, or other significant AR requiring medical intervention after receipt of a vaccine

• Diagnosis of malignancy (excluding nonmelanoma skin cancer)

• Receipt of:

• Any authorized or licensed vaccine within 28 days before the first dose of IP or plans for receipt of any licensed vaccine through 28 days following the last dose of IP or any seasonal influenza vaccine within 14 days before the first dose of IP or plans for receipt of any seasonal influenza vaccine 14 days following the last dose of IP.

• Participated in an interventional clinical study, other than mRNA-1273-P203 study, within 28 days prior to the Screening Visit (Day 0 [for Part 1C-1], BD-Day 0 [for Part 1C-2]) or plans to do so while participating in this study.

Part 1C-2 Heterologous Booster Dose:

• Has a known history of SARS-CoV-2 infection within 2 weeks prior to administration of IP or known close contact with anyone with laboratory-confirmed SARS-CoV-2 infection or COVID 19 within 2 weeks prior to administration of IP.

Related Conditions & MeSH terms

• SARS-CoV-2

Intervention

Biological:
• mRNA-1273
Sterile liquid for injection
• Placebo
0.9% sodium chloride (normal saline) injection
• mRNA-1273.222
Sterile solution for injection

Locations

Country	Name	City	State
Dominican Republic	Caimed Dominicana S.A.S	Santo Domingo	Distrito Nacional
Dominican Republic	Hospital General Regional Dr. Marcelino Velez Santana	Santo Domingo	Distrito Nacional
Dominican Republic	Hospital Materno Infantil San Lorenzo de Los Mina	Santo Domingo	Distrito Nacional
Dominican Republic	Instituto Dermatologico y Cirugia de la Piel Dr. H Sede San Cristóbal	Santo Domingo	Distrito Nacional
Dominican Republic	Instituto Dominicano de Estudios Virologicos IDEV	Santo Domingo	Distrito Nacional
United States	Velocity Clinical Research - Albuquerque - PPDS	Albuquerque	New Mexico
United States	Benchmark Research	Austin	Texas
United States	Velocity Clinical Research - Banning	Banning	California
United States	Cope Family Medicine - Ogden Clinic - CCT	Bountiful	Utah
United States	Tekton Research - Georgia - PPDS	Chamblee	Georgia
United States	Coastal Pediatric Associates	Charleston	South Carolina
United States	Meridian Clinical Research - Charleston, SC	Charleston	South Carolina
United States	Olivo Medical and Wellness Center	Chicago	Illinois
United States	Velocity Clinical Research - Cincinnati - PPDS	Cincinnati	Ohio
United States	IACT Health - Roswell - IACT - HyperCore - PPDS	Columbus	Georgia
United States	Coastal Bend Research Center	Corpus Christi	Texas
United States	Velocity Clinical Research - Providence - PPDS	East Greenwich	Rhode Island
United States	Child Healthcare Associates - East Syracuse	East Syracuse	New York
United States	Alliance for Multispecialty Research -El Dorado	El Dorado	Kansas
United States	Meridian Clinical Research (Endwell-New York) - Platinum - PPDS	Endwell	New York
United States	ACRC Trials	Frisco	Texas
United States	Cyn3rgy Research - ClinEdge - PPDS	Gresham	Oregon
United States	Velocity Clinical Research - Gulfport - PPDS	Gulfport	Mississippi
United States	Meridian Clinical Research (Hastings-Nebraska) - Platinum - PPDS	Hastings	Nebraska
United States	DM Clinical Research - Kool Kids Pediatrics - ERN - PPDS	Houston	Texas
United States	Wee Care Pediatrics - Kaysville	Kaysville	Utah
United States	Paradigm Clinical Research	La Mesa	California
United States	Altus Research - Hunt - PPDS	Lake Worth	Florida
United States	Johnson County Clin-Trials	Lenexa	Kansas
United States	Meridian Clinical Research - (Macon Georgia) - Platinum - PPDS	Macon	Georgia
United States	Velocity Clinical Research - Boise - PPDS	Meridian	Idaho
United States	Velocity Clinical Research - Metairie - PPDS	Metairie	Louisiana
United States	Clinical Research Institute, Inc - CRN - PPDS	Minneapolis	Minnesota
United States	Cottonwood Pediatrics	Murray	Utah
United States	Meridian Clinical Research (Norfolk, Virginia)	Norfolk	Virginia
United States	Coastal Carolina Research Center	North Charleston	South Carolina
United States	Lynn Health Science Institute	Oklahoma City	Oklahoma
United States	Meridian Clinical Research (Omaha-Nebraska) - Platinum - PPDS	Omaha	Nebraska
United States	Quality Clinical Research - HyperCore - PPDS	Omaha	Nebraska
United States	Accel Research Sites - Nona Pediatric Center - ERN - PPDS	Orlando	Florida
United States	Meridian Clinical Research - Family Practice Ports - Portsmouth - Platinum - PPDS	Portsmouth	Virginia
United States	Sundance Clinical Research - Platinum - PPDS	Saint Louis	Missouri
United States	Clinical Trials of Texas, Inc. - PPDS	San Antonio	Texas
United States	Tekton Research	San Antonio	Texas
United States	Tekton Research	San Antonio	Texas
United States	Meridian Clinical Research (Sioux City - Iowa)	Sioux City	Iowa
United States	South Ogden Family Medicine/Ogden Clinic - CCT Research	South Ogden	Utah
United States	Clinical Research Atlanta	Stockbridge	Georgia
United States	Alliance for Multispecialty Research	Syracuse	Utah
United States	Vital Prospects Clinical Research Institute PC - CRN - PPDS	Tulsa	Oklahoma
United States	Velocity Clinical Research - Valparaiso	Valparaiso	Indiana
United States	Advanced Clinical Research - Jordan Valley - ERN - PPDS	West Jordan	Utah
United States	University of Massachusetts Medical School, Molecu	Worcester	Massachusetts

Sponsors (2)

Lead Sponsor	Collaborator
ModernaTX, Inc.	Biomedical Advanced Research and Development Authority

Countries where clinical trial is conducted

United States,  Dominican Republic, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)		Up to Day 187 (7 days after injection/each injection)
Primary	Number of Participants with Unsolicited Adverse Events (AEs)		Up to Day 208 (28 days after dose/each dose)
Primary	Number of Participants with Serious Adverse Events (SAEs), Medically Attended AEs (MAAEs), or Adverse Events of Special Interest (AESI)		Up to Day 751
Primary	Number of Participants With Serum Antibody (Ab) Levels that Meet or Exceed the Threshold of Protection From COVID-19	Acceptable serum Ab threshold as predefined for the study.	Day 57
Primary	Geometric Mean (GM) Value of the Serum Ab Level		Day 57
Primary	Seroresponse Rate (SRR) of Vaccine Recipients		Day 57
Primary	Number of Participants with AEs Leading to Discontinuation From Study Post BD		Up to Day 751
Primary	GM Value of the Serum Ab Level Against Ancestral Strain Post BD		BD-Day 29
Primary	SRR of Vaccine Recipients Against Ancestral Strain Post BD at BD-Day 29		BD-Day 29
Primary	GM Value of the Serum Ab Level Against Ancestral Strain Post Dose 2		Day 57
Primary	SRR of Vaccine Recipients Against Ancestral Strain Post Dose 2		Day 57
Primary	Number of Participants with AEs Leading to Discontinuation from Study from Dose 1		Up to Day 361
Primary	GM Value of the Serum Ab Level After mRNA-1273.222 Vaccine Administration Against SARS-CoV-2 Omicron Variant		Day 29
Primary	GM Value of the Serum Ab Level After mRNA-1273.222 Vaccine Administration Against Ancestral Strain		Day 29
Secondary	GM Value of SARS-CoV-2 Spike Protein (S2P)-Specific Binding Antibody (bAb)		Day 1, Day 57 (1 month after Dose 2), Day 209 (6 months after Dose 2), and Day 394 (1 year after Dose 2)
Secondary	GM Value of SARS-CoV-2-Specific Neutralizing Antibody (nAb)		Day 1, Day 57 (1 month after Dose 2), Day 209 (6 months after Dose 2), and Day 394 (1 year after Dose 2)
Secondary	Number of Participants with a SARS-CoV-2 Infection (Symptomatic or Asymptomatic) Starting 14 Days after the Second Dose of mRNA-1273 or Placebo	Clinical signs indicative of SARS-CoV-2 infection as predefined for the study.	Day 43 up to Day 394
Secondary	Number of Participants With Asymptomatic SARS-CoV-2 Infection Measured by Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) and/or bAb Levels Against SARS-CoV-2 Nucleocapsid Protein		Day 43 up to Day 394
Secondary	Number of Participants with a First Occurrence of Symptomatic COVID-19 Starting 14 days After Second Dose of mRNA-1273 or Placebo	Clinical signs indicative of symptomatic COVID-19 as predefined for the study.	Day 43 up to Day 394
Secondary	GM Value of the Serum Ab Level After mRNA-1273 Vaccine Administration Against Circulating Strain		Day 29
Secondary	SRR After mRNA-1273 Vaccine Administration Against Circulating Strain		Day 29
Secondary	SRR After mRNA-1273.222 Vaccine Administration Against Omicron Variant		Day 29
Secondary	SRR After mRNA-1273.222 Vaccine Administration Against Ancestral Strain		Day 29
Secondary	GM Value of the Serum Ab Level After mRNA-1273.222 Vaccine Administration Against Other Variants of Interest		Day 29

External Links

•   Click here to access the website, http://TeenCoveStudy.com, for additional information for the study, such as Study Overview, Participation, Site Locations, along with contact numbers for each location for the study.